Clinical Trials
97 trialsNCT01196390 2026-06-02
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
NCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT03264547 2025-09-29
EMERALD
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT02003209 2025-08-08
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01772472 2025-07-22
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche
Phase 3 Completed
NCT01275677 2025-07-14
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00769379 2025-06-12
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
National Cancer Institute (NCI)
Phase 3 Completed
NCT01526369 2025-05-09
TH V THL
Cancer Trials Ireland
Phase 3 Completed
NCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01084876 2025-02-11
Compare
Celltrion
Phase 3 Completed
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT03013504 2024-11-06
TROIKA
Prestige Biopharma Limited
Phase 3 Completed
NCT03726879 2024-11-05
IMpassion050
Hoffmann-La Roche
Phase 3 Completed
NCT04957212 2024-07-26
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
Cinnagen
Phase 3 Completed
NCT03425656 2024-06-28
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
AryoGen Pharmed Co.
Phase 3 Completed
NCT03493854 2024-06-26
FeDeriCa
Hoffmann-La Roche
Phase 3 Completed
NCT03084237 2024-05-17
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 3 Completed
NCT05629949 2024-04-23
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT04629846 2024-04-19
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01120184 2024-03-04
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
Hoffmann-La Roche
Phase 3 Completed
NCT03989037 2023-12-27
A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
Shanghai Institute Of Biological Products
Phase 3 Completed
NCT06107790 2023-10-30
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 3 Completed
NCT03262935 2023-10-19
TULIP
Byondis B.V.
Phase 3 Completed
NCT02586025 2023-05-22
PEONY
Hoffmann-La Roche
Phase 3 Completed
NCT01875367 2023-04-05
ChangHER-SC
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT03433313 2023-01-20
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
EirGenix, Inc.
Phase 3 Completed
NCT04109391 2022-10-26
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Tanvex BioPharma USA, Inc.
Phase 3 Completed
NCT03705429 2022-08-19
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Completed
NCT02162667 2022-08-03
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
Celltrion
Phase 3 Completed
NCT01966471 2022-06-14
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02472964 2022-02-14
HERiTAge
Viatris Inc.
Phase 3 Completed
NCT03556358 2022-01-14
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc.
Phase 3 Completed
NCT02896855 2021-12-16
PUFFIN
Hoffmann-La Roche
Phase 3 Completed
NCT00553358 2021-09-21
Neo ALTTO
Novartis
Phase 3 Completed
NCT01989676 2021-07-06
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Pfizer
Phase 3 Completed
NCT00004067 2021-04-29
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
NSABP Foundation Inc
Phase 3 Completed
NCT01566721 2021-04-27
SafeHER
Hoffmann-La Roche
Phase 3 Completed
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT01940497 2020-11-03
SCHEARLY
Hoffmann-La Roche
Phase 3 Completed